The Department of Health and Social Care (DHSC) has said in a supply notification that all formulations of Ranitidine are likely to remain out of stock until further notice.
Ranitidine 50mg/2ml injection is expected to be out of stock by the end of May.
Ranitidine film-coated tablets, effervescent tablets and oral solutions will remain unsupplied until further notice.
All formulations of Ranitidine are affected due to on-going regulatory probe into the presence of the contaminant, N-nitrosodimethylamine (NDMA), in samples of Ranitidine active substance.